Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody

Figure 4

Association of TERT promoter mutations and its immunoreactivity in human gliomas. (a) Immunostaining of TERT by TMab-6 demonstrated that TERT immunoreactivity did not correspond to the mutational status of the TERT promoter region across glioma samples. Semiquantitative analysis of the TERT-immunostaining, scoring the staining intensities as 1+ (a few weakly positive cells), 2+ (positive cells < 50%), and 3+ (positive cells ≥ 50%). Blue dots represent TERT-wildtype cases and red denotes TERT-mutated cases. values for nonneoplastic tissue versus each glioma entity. (b) An analysis on the relationship of the TERT promoter mutations, the expression level of TERT protein and each tumor entity by Western blotting with the most widely used, commercially available TERT antibody (sc-7215). A bar graph showed the quantification of TERT expression in each case, normalized by a loading control GAPDH expression. specific bands. LE, long exposure. AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; CD, cortical dysplasia; DA, diffuse astrocytoma; GBM, IDH-wildtype glioblastoma; HS, hippocampal sclerosis; OA, oligoastrocytoma; OL, oligodendroglioma; IDHwt, IDH-wildtype diffuse astrocytoma; wt/WT, wildtype. Scale bar = 40 μm.

(a)

(b)